AFib May Affect More Than the Heart
Those with atrial fibrillation (AFib) who are over 70 years old may be vulnerable to a decline in physical performance, a new study found.
What to Do When Your Heart Short-Circuits
February is heart health month. And that means it's a good time to learn about one common heart condition that affects more than 2.5 million Americans.
Women, Get Your Heartbeat Checked
Women's hearts are not the same as men's when it comes to a condition called atrial fibrillation (Afib).
The Antidote for Blood Thinners
Bleeding can be a major concern for patients taking blood thinners. But what if the effects of these drugs could be safely reversed in an emergency situation?
Pradaxa Reversal Rx Approved
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
Understanding Atrial Fibrillation
"AFib" may sound like a little white lie, but it’s actually a serious medical condition. Atrial fibrillation, or AFib, is the most common type of heartbeat rhythm problem.
So You've Got Atrial Fibrillation — What's Next?
Atrial fibrillation (AFib) is the most common cause of irregular heartbeat, affecting nearly 2.7 million Americans. If left untreated, it can significantly increase the risk of stroke and other heart problems. But what does an AFib diagnosis really mean?
How to Choose an Anticoagulant
If you need to take an anticoagulant — popularly known as a blood thinner — you don’t want it to cause bleeding, but some might raise your bleeding risk.
Treating Troubled Sleep to Treat a Troubled Heart
Irregular breathing from sleep apnea has been linked to the irregular heart rhythm called atrial fibrillation. Treating sleep apnea, however, may lower the risk of atrial fibrillation happening again.
DOD Study Supports Benefit-Risk Profile of Pradaxa for AFib
Ridgefield, CT, November 17, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System database showing that non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate mesylate) in routine clinical care experienced reduced rates of stroke, major bleeding, death and other types of bleeding, along with increased lower gastrointestinal (GI) bleeding, compared to patients treated with warfarin.